Variables | Total | Survival group | Nonsurvival group | P |
---|---|---|---|---|
EHSS establishment (n) | 90 | 69 | 21 | Â |
 Male [n(%)] | 84 (93.3) | 64 (92.8) | 20 (95.2) | 1.000 |
 Age [year, M(Q)] | 22 (19–32) | 22 (19–26.5) | 27 (20.5–37.5) | 0.066 |
 APACHE II score (x ± s) | 23.5 ± 8.6 | 20.7 ± 7.4 | 32.8 ± 4.7 | 0.048 |
 Vasoactive drugs [n(%)] | 25 (27.8) | 14 (20.3) | 11 (52.4) | 0.013 |
 Cooling effect [n(%)] | 32 (35.6) | 27 (39.1) | 5 (23.8) | 0.161 |
EHSS verification (n) | 80 | 62 | 18 | Â |
 Male [n(%)] | 72 (90.0) | 58 (93.5) | 14 (77.8) | 0.071 |
 Age [year, M(Q)] | 24 (20–30) | 25 (20.7–30.2) | 20.5 (19.7–27.2) | 0.146 |
 APACHE II score (x ± s) | 21.2 ± 7.3 | 18.9 ± 5.9 | 29.1 ± 6.4 | < 0.001 |
 Vasoactive drugs [n(%)] | 29 (36.3) | 17 (27.4) | 12 (66.7) | 0.002 |
 Cooling effect [n(%)] | 35 (43.8) | 29 (46.8) | 6 (33.3) | 0.312 |